CD274 and non-small cell lung carcinoma: Our aim was to carry out a cost-effectiveness analysis (CEA) of 1L therapies (chemotherapy, chemotherapy plus pembrolizumab, and pembrolizumab monotherapy) currently approved by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with metastatic non-squamous NSCLC and PD-L1 expression ≥ 50%, based on recent data from the KN-024 and KN-189 registration trials [4, 6].